Central to PD management are dopamine replacement therapy, levodopa, and other drugs that stimulate the dopaminergic pathway, such as dopamine agonists and drugs that prevent the breakdown of dopamine, such as monoamine oxidase type B (MAO B) inhibitors and catechol-O-methyl transferase (COMT) inhibitors. This evidence concerns the gene MAOB and Parkinson disease.